2016 Russell Ross Memorial Lecture in Vascular Biology
Molecular–Cellular Mechanisms in the Progression of Atherosclerosis

Ira Tabas

Abstract—Atherosclerosis is initiated by the subendothelial accumulation of apoB-lipoproteins, which initiates a sterile inflammatory response dominated by monocyte–macrophages but including all classes of innate and adaptive immune cells. These inflammatory cells, together with proliferating smooth muscle cells and extracellular matrix, promote the formation of subendothelial lesions or plaques. In the vast majority of cases, these lesions do not cause serious clinical symptoms, which is due in part to a resolution–repair response that limits tissue damage. However, a deadly minority of lesions progress to the point where they can trigger acute lumenal thrombosis, which may then cause unstable angina, myocardial infarction, sudden cardiac death, or stroke. Many of these clinically dangerous lesions have hallmarks of defective inflammation resolution, including defective clearance of dead cells (efferocytosis), necrosis, a defective scar response, and decreased levels of lipid mediators of the resolution response. Efferocytosis is both an effector arm of the resolution response and an inducer of resolution mediators, and thus its defect in advanced atherosclerosis amplifies plaque progression. Preclinical causation/treatment studies have demonstrated that replacement therapy with exogenously administered resolving mediators can improve lesional efferocytosis and prevent plaque progression. Work in this area has the potential to potentiate the cardiovascular benefits of apoB-lipoprotein–lowering therapy. (Arterioscler Thromb Vasc Biol. 2017;37:183-189. DOI: 10.1161/ATVBAHA.116.308036.)

Key Words: apoptosis ■ atherosclerosis ■ efferocytosis ■ inflammation ■ macrophages ■ necrosis ■ resolution

This article is based on the 2016 Russell Ross Memorial Lecture in Vascular Biology presented at the American Heart Association Scientific Sessions Annual Conference, November 12 to 16, New Orleans, LA. Although atherogenesis is triggered by the subendothelial retention of apoB-lipoproteins in focal areas of the arterial tree,1,2 the question of how this inciting event leads to the series of complex cell biological processes termed atherosclerosis is perhaps the most fundamental question in this field of research and is the topic of the lecture and this article. It is indeed an honor to have been awarded this lectureship in memory of Dr Ross because it was his paradigm-shifting work in exactly this area that stimulated many of us to focus our research on this question. The evolution of Dr Ross’s concepts on this topic is highly instructive, moving from an initial theory that imagined a role for overt endothelial injury and smooth muscle cell proliferation to one that considered the role of more subtle changes in endothelial function, including inflammatory changes.3,4 Through the work of many researchers from this time forward, including leaders such as Peter Libby, Goran Hansson, and many past Ross Lectureship awardees, the concept that atherosclerosis is driven by inflammation—in essence, the most important response to lipoprotein retention—has been supported by thousands of papers using causation models in mice and observational studies in humans.5,6 Most importantly, work in this area has led to the first anti-inflammation cardiovascular benefits of apoB-lipoprotein–lowering therapy. In the future, work in this area should focus our research on this question. The evolution of Dr Ross’s concepts on this topic is highly instructive, moving from an initial theory that imagined a role for overt endothelial injury and smooth muscle cell proliferation to one that considered the role of more subtle changes in endothelial function, including inflammatory changes.3,4 Through the work of many researchers from this time forward, including leaders such as Peter Libby, Goran Hansson, and many past Ross Lectureship awardees, the concept that atherosclerosis is driven by inflammation—in essence, the most important response to lipoprotein retention—has been supported by thousands of papers using causation models in mice and observational studies in humans.5,6 Most importantly, work in this area has led to the first anti-inflammation cardiovascular benefits of apoB-lipoprotein–lowering therapy. In the future, work in this area should focus on the following questions: What is the trigger for inflammation early in atherogenesis? Although many theories have proposed links to bacterial or viral infections, the evidence is scant. On the other hand, we know that an early event in atherogenesis is the subendothelial retention of plasma-derived apoB-lipoproteins, notably low-density lipoprotein (LDL) and chylomicron remnants.1,2 These lipoproteins accumulate at sites of disturbed flow in medium-sized
arteries—sites that are uniquely destined to become filled with atherosclerotic plaque. Lipoprotein retention occurs before the appearance of inflammatory cells,\(^5,6\) and blocking retention through genetic engineering or other means blocks early atherogenesis in mice.\(^11,12\) Most importantly, drugs that lower apoB-lipoproteins have shown unequivocal cardiovascular and mortality benefit in millions of subjects and over decades of clinical study,\(^13\) and there is now convincing genetic evidence linking mutations that affect apoB-lipoprotein retention itself by promoting permeability and possibly transcytosis,\(^26\) and flow-mediated activation likely primes endothelial cells to respond to the subsequent inflammatory stimulus of retained lipoproteins.\(^27\) However, the fact remains that atherosclerosis will not form at sites of endothelial activation if the level of apoB-lipoproteins falls below a certain threshold level, whereas atherosclerosis will form at nonflow-disturbed sites if apoB-lipoproteins rise to high levels.\(^1,2\)

Second, how can the overall lowering of plasma LDL over the past 3 decades, that is, after the introduction of statins, be reconciled with the fact that atherosclerotic vascular disease remains the leading cause of death?\(^28\) Despite the enormous life-saving success of statins, issues related to potency, real or perceived drug safety and side effects, patient compliance, and patient and provider education have limited our ability to lower LDL to the types of level, and at an early enough age, that would be needed to remove atherosclerotic disease from the leading killer list.\(^29\) The availability of PCSK9 inhibitors may help us get closer to this goal.\(^30\) However, these efforts are being counterbalanced by the worldwide epidemic of obesity and insulin resistance, which are conditions that lower the atherogenic threshold to apoB-lipoproteins.\(^31\) Thus, more intense lipoprotein lowering is needed to achieve the same result in the face of this epidemic, which is predicted to continue well into the 21st century.\(^32\)

### Progression of Atherosclerosis

There have been many excellent reviews on the series of atherosclerotic events that occur after lipoprotein retention and the initial entry of monocytes, and I refer to some of these with only brief outline here.\(^33–40\) The subendothelial areas that initially accumulate lipoproteins, referred to as intima, expand as a result of (1) increasing numbers of both innate and adaptive inflammatory cells through continual entry and proliferation, (2) proliferation of myofibroblast cells that originate from vascular smooth muscle cells (VSMCs), and (3) extra-cellular lipid and matrix molecules. Each of these processes has been studied widely and is driven by complex processes involving hundreds of molecules and various combinations of cell–cell interactions. I would like to emphasize here 2 key points about the progressing lesion. First, lipoprotein retention is amplified as lesions progress,\(^31\) probably as a result of the synthesis of apoB-lipoprotein–binding proteoglycans by inflammatory cells. Therefore, the inflammatory response to these lipoproteins is persistent and amplified.\(^12\) Persistence of a sterile inflammatory stimulus creates a scenario of chronic, nonresolving inflammation, analogous to what occurs when a splinter is not removed from a finger—or, more accurately, if additional splinters were continually added to the inflamed digit. Second, despite the expansion of the intima, the lumen remains patent because of outward remodeling and compensatory enlargement of the arterial wall.\(^32\) Thus, atherosclerosis at this stage is largely asymptomatic. Indeed, in any given individual with multiple atherosclerotic lesions, the vast majority of lesions—perhaps as many as 95%—will not cause acute thrombo-occlusive vascular disease.\(^41\)

With this scenario in mind, one of the most important goals in atherosclerosis research is to understand the unique molecular and cellular events that lead to the formation of the small minority of plaques that account for virtually all acute atherothrombotic vascular events, including unstable angina, myocardial infarction, sudden cardiac death, and stroke. Recent pathological analyses suggest that these clinically dangerous plaques fall into 2 categories\(^42:\) (1) those that have numerous inflammatory cells, lipid-rich necrotic cores, and thin collagenous fibrous caps that overlay the core and (2) those that are characterized by an abundance of extracellular matrix and endothelial apoptosis. Necrotic plaques, which are often called vulnerable plaques, can precipitate all categories of acute atherothrombotic events but are particularly associated with ST-segment–elevation myocardial infarction. These plaques have been widely studied, and much is known about the mechanisms that lead to their formation and their thrombotic consequences, as described below. Less is known about the matrix-rich category of dangerous plaques, which is often associated with non–ST-segment–elevation myocardial infarction.\(^44\) On the basis of the results of in vitro experiments and in vivo observations, the mechanism of plaque erosion may involve prothrombotic activation and death of endothelial cells via activation of Toll-like receptor 2.\(^45\)

In contrast, necrotic plaques are susceptible to frank rupture, which triggers acute lumenal thrombosis via exposure
of blood platelets to procoagulant/thrombotic factors, notably tissue factor, in the necrotic core.43 Moreover, necrotic cores are filled with DAMP-like molecules,46,47 which amplifies the inflammatory response. The mechanism of necrotic core formation involves the death of lesional cells, mostly macrophages but also smooth muscle cells,46 coupled with poor phagocytic clearance of these dead cells by a process called efferocytosis.54 In the setting of defective efferocytosis, the initially intact membranes of apoptotic cells begin to break down, leading to a type of cellular necrosis known as postapoptotic, or secondary, necrosis. There is also evidence that primary necrosis, or necroptosis, of lesional macrophages triggered by receptor-interacting serine/threonine-protein kinase 3 contributes to plaque necrosis in advanced atherosclerosis.59–61 The consequences of necroptosis may also be exacerbated by poor phagocytic clearance of cells that die by this process.52 Plaque rupture occurs as a result of fibrous cap thinning, which has been ascribed to death of collagen-producing intimal smooth muscle cells and to the production of various types of matrix-destroying proteases by lesional inflammatory cells.53 In addition, physical properties of the lipid-rich necrotic core creates a physical strain on the overlying fibrous cap that can contribute to plaque rupture.54

Defective Resolution in Plaque Progression

We and others have sought to construct a unified conceptual framework that could help explain the series of molecular and cellular events leading to the formation of clinically dangerous plaques. The concept is based on the seminal studies of Nathan, Serhan, and others that have educated us about an active resolution and repair process that occurs during and immediately subsequent to the inflammatory response.55,56 In order for the inflammatory response to be effective in defense against pathogens, numerous pro-oxidant- and protease-secreting inflammatory cells must invade the site of infection, which inevitably causes collateral tissue damage. Thus, we have evolved mechanisms to repair this damage and return to tissue homeostasis through the action of numerous types of resolution mediators. These mediators are delivered at both the onset of the inflammatory response, for example, as neutrophil-derived secretory factors in edema fluid, and after pathogen neutralization, for example, by recruitment of reparative cells, including macrophages that have a resolution phenotype. Resolution is mediated by (1) endogenous lipids that are generated during inflammation, including lipoxins, resolvins, protectins, and maresins, called specialized proresolving mediators (SPMs), (2) proteins, such as interleukin (IL)-10, transforming growth factor-β, and annexin A1, (3) bioactive gases such as nitric oxide, hydrogen sulfide, and carbon monoxide, and (4) resolving cells, such regulatory T cells and I would argue that it may be the linchpin in the progression to plaque vulnerability.63,64,66 Efferocytosis is mediated through phagocyte receptors, apoptotic cell ligands, bridging proteins, and chemoattractants. It is normally a high-capacity and efficient process, but when it goes awry, tissue necrosis and subsequent DAMP-mediated inflammation occurs.74–76 Macrophages in clinically dangerous human coronary plaques show evidence of defective efferocytosis, that is, there are abundant uncleared dead cells, and this defect correlates with 2 key features of these plaques—necrosis and inflammation.63,64,69,72 Causation is suggested by studies using genetically altered mice. For example, when efferocytosis is compromised through gene targeting of effector molecules, there is an increase in uncleared apoptotic cells, inflammation,
Our and another laboratory demonstrated this principle using athero-prone mice lacking the macrophage efferocytosis receptor MerTK. The mechanism of defective efferocytosis in advanced plaques represents a major gap in this field. Overwhelming apoptosis is not likely to be a major factor in view of the high-capacity nature of efferocytosis. For example, when apoptosis is increased in early atherosclerosis, where efferocytosis is not defective, apoptotic cells are efficiently cleared. Although it is possible that death or a phenotypic change in advanced lesional macrophage death limits efferocytosis by decreasing the pool of competent efferocytes, advanced lesions have a substantial population of living phagocytes. Moreover, we showed that cholesteryl ester loading of macrophages does not compromise efferocytes and that macrophages undergoing efferocytosis acquire resistance to cell death stimuli. Rather, we favor the hypothesis that specific molecular–cellular processes involved in the recognition or uptake of apoptotic cells by lesional macrophages compromise efferocytosis in advanced atherosclerosis. For example, a recent study showed that some apoptotic cells in lesions continue to display a don’t-eat-me molecule called CD47, which is usually lost on apoptosis, thus preventing the uptake of these dead cells. As another example, the macrophage MerTK receptor, which as indicated above plays an important role in advanced lesional efferocytosis, can be disabled by disintegrin and metalloproteinase domain–containing protein 17 (ADAM17)–mediated proteolytic cleavage under exactly the types of inflammatory conditions that occur in advanced atherosclerosis. Indeed, macrophages near the necrotic cores of human plaques demonstrate high ADAM17 expression and low levels of cell surface MerTK. In human carotid artery endarterectomy specimens, we found a strong correlation between the level of the stable product of MerTK cleavage, soluble Mer, and both advanced plaque stage and the presence of ischemic symptoms. Finally, Western diet-fed Ldlr−/− mice expressing a genetically engineered mutant of MerTK that cannot be cleaved showed enhanced lesional efferocytosis and decreased plaque necrosis.

Efferocytosis is one of the most important cellular effector arms of the resolution program. Inflammation results in the accumulation of enormous amounts of dead cells, notably neutrophils, and resolution mediators have been shown to promote efferocytosis both in vitro and in vivo. A fascinating topic to consider is whether efferocytosis is also a mediator of the resolution response, which would amplify the response as part of a positive-feedback process. Evidence...
to support this concept is suggested by studies showing that phagocytes increase SPM production when engulfing apoptotic cells,\textsuperscript{93,94} and we showed recently that activation of the MerTK receptor in macrophages with an activating antibody, the MerTK ligand Gas6, or apoptotic cells promoted the synthesis of SPMs.\textsuperscript{95} The mechanism involves MerTK-mediated stimulation of nuclear-to-cytoplasmic translocation of 5-LOX (lipoxygenase), which increases the synthesis of SPMs through the 12,15-lipoxygenase pathway.\textsuperscript{96} We have shown that this proresolving action of MerTK is disabled by MerTK cleavage and important in several models of sterile inflammation, including atherosclerosis.\textsuperscript{90,95}

**Summary and Conclusions**

Atherosclerosis is a heterogeneous disease despite a common initiating event, subendothelial retention of apoB-lipoproteins. In the vast majority of lesions, the sterile inflammatory response to these retained lipoproteins does not lead to acute thrombotic complications. The most likely explanation is that an adequate resolution response is mounted, when effecrocytosis prevents plaque necrosis and a reparative scarring response (the fibrous cap) prevents plaque disruption. Elements of the resolution response may also promote endothelial health in the setting of inflammation and thereby prevent plaque erosion.\textsuperscript{97} However, for reasons that remain to be elucidated, a small percentage of developing atherosclerotic lesions cannot maintain an adequate resolution response, leading to the formation of the types of clinically dangerous plaques that can trigger acute luminal thrombosis and tissue ischemia and infarction. It is likely that a series of amplified pathophysiologic processes spin out of control to create these rare but deadly plaques. We think that defective effecrocytosis is a major contributor to this series of events, with several new studies providing plausible mechanisms of how effecrocytosis becomes defective in advancing plaques. Once effecrocytosis becomes defective and postapoptotic necrosis occurs, anti-inflammatory and proresolving pathways downstream of effecrocytosis are lost, and DAMPs arising from the necrotic cells exacerbate the inflammatory response. A fascinating question that emerges from this scenario is what determines whether any given lesion will undergo this transformation. Is it stochastic, or is there a specific determinant, such as excessive apoB-lipoprotein accumulation occurring earlier in the history of the fated lesion?

Throughout this review, I have emphasized the clinical importance of advanced plaque progression as the cause of acute atherothrombotic events, and I have highlighted several critical questions related to mechanisms of plaque progression that remain to be addressed. However, one may legitimately question whether research in this area has therapeutic potential in the face of the logical conclusion that if apoB-lipoproteins could be brought safely below a certain threshold level at an early enough age in all individuals, atherosclerotic vascular disease would be eliminated. Even with established atherosclerosis, lesions can regress if the apoB-lipoproteins are brought to a low enough level.\textsuperscript{98} In this context, a prominent editorial 20 years ago suggested that coronary disease may no longer be a major health problem by the early 21st century.\textsuperscript{98} However, for the reasons discussed earlier in this review, that is, cholesterol-lowering drug--related issues and the epidemic of insulin resistance, atherosclerotic vascular disease remains the leading cause of death 2 decades into the 21st century. Although continued work on achieving lower and earlier LDL, stemming the epidemic of obesity and insulin resistance, and ameliorating other risk factors is critical, I think that further understanding the mechanisms of advanced plaque progression should also be a priority. Research in this area may be able to suggest ways to raise the atherogenic threshold to apoB-lipoproteins such that, through combined apoB-lipoprotein--lowering and arterial-wall therapy, currently achievable levels of apoB-lipoprotein lowering can be disease ending. Accordingly, we await the results of the aforementioned anti-inflammatory trials that are currently underway in humans,\textsuperscript{7,8} and several new therapeutic concepts have emerged based on the pathophysiology of plaque progression, including the use of exogenous resolving mediators and drugs that suppress cellular necrosis.\textsuperscript{51,66,99}

**Sources of Funding**

The research in the author’s laboratory covered in this review was supported by National Institutes of Health grants HL075662, HL127464, and HL132412.

**References**

13. Mihaylova B, Emerson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease:


2016 Russell Ross Memorial Lecture in Vascular Biology: Molecular–Cellular Mechanisms in the Progression of Atherosclerosis
Ira Tabas

Arterioscler Thromb Vasc Biol. 2017;37:183-189; originally published online December 15, 2016;
doi: 10.1161/ATVBAHA.116.308036
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/37/2/183

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org/subscriptions/